Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.

Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD and pharmaceutical compositions thereof.

Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.

Abstract: A high-efficiency power amplifier is provided, including a drive amplifier and a final power amplifier, and further including a first digital pre-distortion (DPD) correction module and a second DPD correction module. The first DPD correction module is configured to pre-distort nonlinear characteristics of drive signals output by the drive amplifier, and the second DPD correction module is connected to the first DPD correction module in series, and is configured to pre-distort nonlinear characteristics of amplified signals output by the final power amplifier. Another high-efficiency power amplifier is also provided, including a drive amplifier and a final power amplifier, and further including a second multi-path control module, a fourth DPD correction module, and a second gating module. The overall efficiency of the high-efficiency power amplifier is increased by improving the working efficiency of the drive amplifier.

Abstract: A high-efficiency power amplifier is provided, including a drive amplifier and a final power amplifier, and further including a first digital pre-distortion (DPD) correction module and a second DPD correction module. The first DPD correction module is configured to pre-distort nonlinear characteristics of drive signals output by the drive amplifier, and the second DPD correction module is connected to the first DPD correction module in series, and is configured to pre-distort nonlinear characteristics of amplified signals output by the final power amplifier. Another high-efficiency power amplifier is also provided, including a drive amplifier and a final power amplifier, and further including a second multi-path control module, a fourth DPD correction module, and a second gating module. The overall efficiency of the high-efficiency power amplifier is increased by improving the working efficiency of the drive amplifier.

Abstract: Compounds of formula A: and pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by Raf kinases.

Abstract: A new class of reagents and method of use of the reagents in the reaction of the reagents with electrophilic compounds. The invention in one embodiment is directed to a method for the formation of an alcohol of the formula (I). The method includes reacting a reagent of the formula (II) with an aldehyde of the formula R10CHO to form the alcohol. X3 is one of O and C(R4)(R5). Each of X1 and X2 is independently O or N—R. Each of Ca and Cb is independently an achiral center, an (S) chiral center or an (R) chiral center. Ra and Rb are (i) each independently C1-10 alkyl, C6-10 aryl or C3-9 heteroaryl, or (ii) taken together to form a C3—C4 alkylene chain which together with Ca and Cb forms a 5-membered or 6-membered aliphatic ring. Rc and Rd are each independently hydrogen, C1-10 alkyl, C6-10 aryl or C3-9 heteroaryl. R is C1-10 alkyl, C6-10 aryl or C3-9 heteroaryl.

Abstract: A new class of reagents and method of use of the reagents in the reaction of the reagents with electrophilic compounds. The invention in one embodiment is directed to a method for the formation of an alcohol of the formula (I). The method includes reacting reagent of the formula (II) with an aldehyde of the formula R10CHO to form the alcohol. X3 is one of O and C(R4)(R5). Each of X1 and X2 is independently O or N—R. Each of Ca and Cb is independently an achiral center, an (S) chiral center or an (R) chiral center. Ra and Rb are (i) each independently C1-10 alkyl, C6-10 aryl or C3-9 heteroaryl, or (ii) taken together to form a C3-C4 alkylene chain which together with Ca and Cb forms a 5-membered or 6-membered aliphatic ring. Rc and Rd are each independently hydrogen, C1-10 alkyl, C6-10 aryl or C3-9 heteroaryl. R is C1-10 alkyl, C6-10 aryl or C3-9 heteroaryl.